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Abstract
Misexpression of germline genes like Cancer Testis (CT) genes, called a soma-togermline transformation, is a phenomenon linked to tumorigenesis. However, the
mechanisms underlying this phenomenon are poorly understood. A soma-to-germline
transformation in Caenorhabditis elegans occurs due to the loss function of the highly
conserved DREAM (Dp, Retinoblastoma (Rb)-like, E2F, and MuvB) transcriptional
repressor complex. In mammalian cells, the DREAM complex (Muvb core complex,
E2F4/5, DP1/2, and p130/p107 proteins), as well as the Retinoblastoma protein (pRb),
are implicated in transcriptional repression of cell cycle genes in quiescence or G0. We
hypothesize that the expression of CT genes in malignant cells occurs because of the loss
of activities of DREAM complex or pRb, similar to how the soma-to-germline
transformation occurs in C. elegans. Thus, we expect that cancer cells that express CT
genes will either fail to arrest in G0 or display defective repression of key cell cycle
genes. To test sensitivity cells to arrest in response to limiting growth conditions, we did
flow cytometry to measure the DNA content of 10 cell lines. We found that seven cell
lines arrested in G0/G1, indicating that these cells have downregulated CT genes
expression, and DREAM or Rb is involved in repressing cell cycle in G0/G1. This result
also suggested that in the cells that did not arrest, both DREAM and Rb are inactive.
Next, to test the mRNA expression of CT genes of all the cell lines, we did mRNA
analysis of CT genes. We found that CT genes are expressed in proliferating cells of both
cells that can arrest under limiting growth conditions and the cells that do not, indicating
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we did not observe a difference in mRNA expression between cells that arrest and cells
that do not. To test if CT misexpression is associated with dysfunction in either Rb or
DREAM, we did further analyses to test early and late cell cycle genes expression in
SW480, NCI-H1299, and 8MGBA, comparing the expression of cell cycle cells in
proliferating cells to arrested cells in G0/G1. We found that mRNA expression of early
cell cycle genes MCM5, ORC1, and CDC45 are downregulated, as expected since
DREAM and Rb regulation of these genes overlap. However, DREAM solely regulates
G2/M genes like CCNB2, PBK, and BUB1. We found that G2/M genes were not in
significantly downregulated in NCI-H1299 and SW-480 cells, suggesting that DREAM is
dysfunctional in these cell lines. As a secondary test of DREAM and Rb function, we
performed luciferase reporter assays with promoters of DREAM and Rb target genes in
SW480 and NCI-H1299 cell lines. Surprisingly, we observed that Rb is dysfunctional in
SW480 cells. Together, these studies will facilitate future studies into the link between
cell cycle regulation and CT upregulation in cancer cells.
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1.1 Introduction
Cancer is a very dynamic complex disease. Over time, it develops from
accumulations of genetic and epigenetic alternations as a result of mutations that cause
uncontrolled cell division [1]. There are estimated numbers that approximately 1 million
new cancer incidences annually in males and more than 900,000 in females between 2010
and 2020 in the U.S. The majority of cancer types expected to increase in males are
melanoma, prostate, and kidney cancer. Moreover, breast, lung, and uterine cancer are the
most cancer types expected to increase in females [2].

Despite the rapid advance in the fields of biological sciences in an understanding
of molecular cancer genetics, how normal cells acquire the malignant characteristics is
not completely understood. There are traits that normal cells acquire to transform into
cancer are called "Hallmarks of Cancer" [3]. Each hallmark contributes to cancer and can
help to understand tumor pathogenesis and the complexity of cancer.

Normal cells have many regulators and pathways that control cell division and
prevent DNA damage. Some of these regulators promote cancer development if they are
inactivated. For example, one of the critical regulators is the Retinoblastoma (Rb) protein
which is inactivated in many human cancerous [4]. The Rb family proteins including

1

Rb/p105, Rb2/p130, and p107 control cell cycle progression and DNA replication
through interaction with E2F to regulate the gene expression of a set group of genes [5].
Both The retinoblastoma pRb and DREAM have similar functions in that they
induce transcription repression in G0/G1 by interaction with E2F elements. DREAM has
a distinct function from pRb/E2F that it regulates many of cell cycle genes involved in
DNA replication, chromosome segregation, DNA repair, histone modification, and
chromatin organization including BRCA1, BRCA2, FANCD1, FANCA, CDC6, CDK2,
and EZH2 because it can bind to both E2F and CHR sites [6].

The p53-p21-DREAM pathway controls the cell cycle through downregulation
the expression of many genes that are involved in cell cycle progression. It regulates
more than 250 genes that are associated with cell cycle progression. This pathway targets
genes from the G1, G2, and M phase [7]. Thus, it controls all checkpoints, including G1,
S, G2, and M. Defects in genes that regulate cell cycle cause aberrant checkpoint control
that promotes aneuploidy and chromosomal instability in cancer cells [8].

Previous studies reported that Cancer/testis (CT) genes are ectopically activated in
many human cancerous under pathogenesis conditions. CT genes have a pattern of
expression that is restricted to normal and tumor cells [9]. Since then, many studies have
emerged to address the factors or mechanisms that contribute to re-repression CT genes
in human cancer cells. However, the mechanisms that drive the activation of CT genes in
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somatic cells still unknown. Therefore, we propose that the activation of CT genes may
be a result of the dysfunction of both transcriptional repressors RB and DREAM in
mammalian cells.

3

1.1.2 The six hallmarks of cancer cells
Cancer cells display unique traits or hallmarks that promote uncontrolled
proliferation and malignancy as compared to normal somatic cells. Six cancer hallmarks,
in particular, have been defined. These include self-sufficiency in proliferation signals,
inactivation of tumor suppressors, enabling of replicative unlimitedly, activation of
invasion and metastasis, stimulating angiogenesis, and resistance to cell death [3].
Alterations of many functionally overlapping molecular pathways govern the prevalence
of each cancer hallmark in a given tumor type. There is a need to identify the potential
causes that drive these alternations in all types of cancers. Therefore, research into the
molecular pathways that contribute to these six cancer hallmarks continues to drive the
development of new methods to combat cancer.

Regarding the first hallmark, genetic or epigenetic alternations in tumors enable
them to require the ability to sustain signals that promote chronic division and
proliferation [3] [10]. Many of genetic and epigenetic changes are oncogenic mutations
that affect signaling pathways, leading in turn to an anti‐apoptotic potential, deregulated
mitogenic, and increased motility in tumor cells [11]. For instance, increased pRb
phosphorylation leads to loss of Rb function, and it occurs in most cancer types [12].
Oncogenic mutations cause upregulation of transcription of cyclin-dependent kinase
(CDK) that mediate phosphorylation of pRb during the transition from G1 to S phase. It
occurs in response to proliferative signals, that causes it to release of E2F, which
promotes entry into S phase [13]. Inactivation of the tumor suppressor signaling
4

pathways leads to remove negative regulators of signaling that play an essential role in
proliferation and progression in cancer cells [10].

Regarding the second hallmark, pRb and p53 functions are inactivated in most
tumor cells and are a typical example of cancer cells evading tumor suppressor pathways
[3]. These proteins have the role of suppressing and controlling cell growth and inducing
senescence (cellular aging) and programmed cell death (PCD) [14]. The p53 gene
regulate many functions of the cell cycle, including repairing damaged DNA, arresting
growth, and apoptosis [15]. Gain- or loss-of-function in pRb or p53, which regulates
proliferation, can trigger senescence, a normal process involving the irreversible arrest of
normal cells [16] [17]. For instance, loss of function in p53 causes defects in cell cycle
checkpoints and DNA damage repair, leading to chromosomal instability and increased
mutation rates [18]. The majority of human cancer have mutated pRb or p53 genes
because of the loss of functions of p53 and pRb pathways that promote tumorigenesis and
tumor progression [19].

The third hallmark of tumor cells is their ability to resist cell death, or apoptosis
[3]. Apoptosis is a tightly controlled mechanism involving energy-dependent cascades
[20]. Apoptosis has two pathways: the intrinsic or mitochondrial pathway and the
extrinsic pathway. The intrinsic signaling pathway involves intracellular signals that are
regulated by the mitochondria [20]. In the latter case, the cell receives cell-death signals
from outside itself, which induce cellular suicide [21]. The evading of apoptosis in cancer
cells can occur by different mechanisms, such as the loss of function of the p53,
5

overexpression of survival signals for example Igf1/2 during the cell death pathway, and
overexpression of antiapoptotic Bcl-2 proteins that regulate apoptosis by binding to
proapoptotic triggering proteins such as Bak and Bax, thereby suppressing their functions
[22]. In cancer cells, there is an imbalance between cell death and cell proliferation, and
the cells that should undergo apoptosis did not receive apoptotic signals. Therefore,
understanding apoptosis is essential because it can give us insight into the pathogenesis
and design an effective treatment of cancer.

The fourth hallmark of cancer cells is their capacity for replicative immortality
[3]. The telomere, which is made by telomerase enzyme, is cap-like nucleoproteins found
at the tips of chromosomes to protect them from fusion and stabilizes the chromosome
and the DNA replication process in the eukaryotic cells [23] [24].

Normal human somatic cells pass through multiple cell divisions, then enter
senescence and then eventually apoptosis. During multiple replication cycles, the
telomeres shorten, and telomerase activity becomes repressed. However, in cancer cells,
telomerase typically activated during immortalization [25]. Due to either genetic or
epigenetic alterations, in malignant tumors, the telomerase lengthens; the tumor cells thus
show high levels of telomerase activity during the process of immortalization, leading to
chromosomal instability [26]. Telomere length besides telomerase activity play a crtical
role in oncogenesis. Thus, it is important to focus on understanding the mechanisms that
trigger the reactivation of telomerase in cancer cells, because it can help to discover
promising biomarkers that can contribute to detect cancer at early stages [27].
6

The fifth hallmark is the initiation of tumor angiogenesis processes, which is the
secretion of angiogenic growth factor proteins by cancerous tumors that stimulate to form
new blood and lymphatic vessels [3]. Cancer cells form new vascular network because of
proliferation, and metastatic spread requires access to oxygen, nutrition, and removal of
the waste products [28]. It allows cancer cells to leave the primary site and migrate
through the bloodstream to invade secondary sites to form colonies, as well as to
metastasize in the late stages of the disease [3]. Previous histological studies on human
tumors have considered a link between p53 and angiogenesis. Tumors with mutated p53
are significantly more vascularized and aggressive than those that have retained
functional p53 [29]. The angiogenesis process is essential for cancer cells because it
enables them to form vascular networks through the bloodstream from the primary site
and migrate to settle a secondary site or metastasis site. Therefore, prevention of tumor
angiogenesis processes can combat neoplastic growth at the primary site and prevent
metastasis of tumor in late-stage, that will allow for treatment by therapeutics.

The sixth hallmark is that tumor cells can penetrate surrounding tissues and
metastasis. Metastasis is observed when malignant tumors migrate from the primary site
by the bloodstream or lymph vessels, to form new tumors at other locations [3]. The
tumor cells interact both cell-to-cell and within the extracellular matrix (ECM). The ECM
contributes to changes in cell adhesion, thus providing a conducive environment in which
the tumor can grow. The pRb protein can mediate these pathways and contribute to
dissociating tumor cells from their original location [12]. Metastasis may occur due to
defects in the epidermal growth factor receptor (EGFR), which regulates the cellular and
7

homeostatic proliferation of epithelial tissues in normal cells [30]. Analysis of EGFR
expression levels in vitro shows that metastatic cells are highly expressive of EGFR when
compared with non-metastatic cells in human colon cancer (HCC) [31]. Besides the focus
on developments of methods to detect the tumor at an early stage. It is crucial to
understand the mechanisms underlying the metastasis because once tumors spread and
migrate from the original site, they can be incurable and fatal [32].

The six cancer hallmarks that cancer cells are acquired to develop tumors are
important to understand the pathogenetic mechanisms of a very complex disease such as
cancer, and to support therapeutic strategies to fight this disease. They are including
stimulating proliferative signaling, inactivating growth suppressors, enabling replicative
unlimitedly, resisting apoptosis, inducing angiogenesis, enabling invasion, and metastasis
[3].

pRb and p53 are significant players in cancer development. However, many
questions remain as to how pRb and p53 regulate cell cycle genes, and how Rb and
DREAM overlap different in their functions to repress cell cycle genes in G0, G1, S, G2
and M phase.

Since it is known that p53 acts as repressor and activator, how its functions can
influence the p53-DREAM pathway is still not completely understood. Besides, the
mechanism of repression cell cycle genes indirectly by the p35-DREAM pathway
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remains unsolved issues, and it is a big challenge for scientists because it showed
unexpected findings that are raising new questions.
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1.1.3 Dysregulation of pRb is associated with tumor
development
pRb is the first known tumor suppressor that regulates cell cycle progression [50].
The Rb family consists of three homologs, pRb (RB1), p107 (RBL1), and p130 (RBL2),
also known as pocket proteins [51]. The retinoblastoma protein inhibits gene transcription
by activating the E2F-DP transcription factor at E2F sites to repress gene expression of
genes required in transition from G1 to S phase leading to cell cycle arrest at early G1
phase [52]. Genetic studies of knockout Rb genes show that they have many functions
and participate in multiple cellular processes such as gene expression and regulation,
cancer development, and cell cycle control [53]. The retinoblastoma tumor suppressor
gene (RB) is inactivated in the most of human cancers due to direct mutation or deletion,
such as small-cell lung carcinoma, and retinoblastoma, or indirectly by alterations of the
activities of the upstream regulators [54].

In tumor cells containing oncogenic mutations, the Rb pathway is disruption.
Following mitogenic stimulation, P21/CDKN1A inactivate cell cycle by inhibiting
cyclin-dependent kinases (CDKs) function that cause phosphorylate of the pocket
proteins p107/p130 [55]. Phosphorylation of Rb proteins leads to release of E2F from
inhibition and activate of the cell cycle genes that are required for S phase entry [52].

The pRb regulates cell division in the nucleus by preventing the progression of
the cell cycle. In normal cells, Rb is found in non-phosphorylated status, and bound to
10

E2Fs in G0/G1 [52]. During the phosphorylation of Rb that occurs by cyclin D-CDK4
and cyclin D-CDK6, it prevents Rb association with E2Fs. Thereby, it facilitates E2Fs to
activate the transcription of genes that are essential for S phase entry [56]. Altered
expression of cell cycle regulators, including cyclin D, CDK4, and their principal
inhibitor p16, is very common in cancer cells. By the end of G1, binding cyclin proteins
cause inactivation by cyclin cd complex. This inactivation causes pRb to release bound
E2F transcription factors, which promote the expression of genes that are essential for
cell progression from G1 to S phase [56]. Loss of functions of Rb is common in the
majority of human cancers by different mechanisms. For instance, inactivation of Rb in
human papillomavirus (HPV) is a result of E7 which is oncogenic protein that binds to
Rb and inhibits its activity from repress damaged cells leading to cell proliferation [57].

Overlapping activations of pRb/E2F and DREAM are required for cells to enter
G0 or quiescence through indirectly repression by the p53-DREAM pathway. The
pRb/E2F and DREAM complexes promote cell cycle arrest via CHR or E2F sites in
G0/G1 phases. Rb and its related proteins p130 and p107 have a master function to
repress gene transcription by binding to E2F sites and inhibit their activities during G1 to
S phase transition [7].

The pRb-related proteins p130/p107 become hypophosphorylated as a result of
the expression of p21/CDKN1A that leads to gathering proteins that are involved in
formation DREAM complex for repressing transcription through E2F or CHR promoter
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sites. The p130/p107, E2F4, and E2F5 are bound via E2F cities during transcriptional
repression of the cell cycle [50].

The p130/p107 are essential components of the DREAM complex that mediate
gene repression [7]. Because of that, knockdown pocket proteins p107/p130 lead to a loss
of DREAM function as a transcriptional repressor [58]. However, how pRB/E2F and
DREAM complexes overlap functions to coordinate cell cycle checkpoints remains
unclear.
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1.1.4 DREAM complex pathway in repression cell cycle genes
DREAM complex is a highly conversed protein that represses cell cycle genes
during quiescence in mammalian cells [6]. It is composed of p107 or p130, E2F4-5/DP
and MuvB core (figure 1) [58] [68]. It plays a critical role in the downregulation of cell
cycle gene expression through quiescence and early G1 [69]. It binds to DNA promoters
via the cell cycle genes homology region (CHR) or E2F sites through the cell cycle. It
also binds CLE (CHR like element) and CDE (cell cycle-dependent element) sites on
DNA. However, it cannot bind to DNA sites by CDE or CLE alone; it requires support by
either CHR or E2F [70].

Figure 1 DREAM complex components in mammalian cells. DREAM binds
E2F/CHR or E2F/CLE, and CHR/CDE sites during G0/G1 to repress the transcription of
the cell cycle genes in G0 and early G1 based on [7].
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Cell cycle genes have a repression mechanism indirectly through the p53-p21DREAM pathway. In G0/G1, cell cycle genes are repressed by the interaction of
DREAM complex and RB-E2F through E2F sites on DNA [71]. In respond to DNA
damage, p53 becomes activated, which leads to induce the expression of p21/CDKN1A.
It produces p21 that form p21/CDKN1A that interacts with cyclin-dependent kinases
(CDKs) and inhibits activity. It leads to phosphorylate the pRB-related proteins p107, and
p130. As a result of that, p107 and p130 become hypophosphorylated and can form
DREAM complex with other proteins to repress the transcription by binding DREAM to
E2F or CHR sites [7]. In late G1, and early S phase, DREAM complex dissociates from
repressive components E2F/pRB and p107and p130 and binds to transcriptional
activators B-MYB to form B-MYB-MuvB complex that switch the repression to
activation.
In late S and early G2 phase, FoxM1 (Forkhead box M1) binds to the complex
and form FOXM1-MMB complex. The B-MYB and FoxM1 coordinate gene expression
of many cell cycle genes during S and G2/M phases [72]. The MuvB core comprises of
LIN9, LIN37, LIN52, RBBP4 proteins, and LIN54, in contrast to the DREAM complex,
it does not have the E2F, Rb, and DP proteins and only binds to CHR promoter sites [7].
MuvB interacts with BMYB and FOXM1 to regulate gene expression through S phase
and G2/M [6]. Because MuvB based complex can change its formation, it binds to BMYB or FoxM1 and forms B-MYB-MuvB (MMB) that turns repression to activation
when LIN54 binds to CHR site with peaks expression in G2/M phases [7].
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p53-DREAM pathway is a critical pathway because it contributes to cell cycle
arrest, and it represents a promising therapeutic target for cancer. Disruption of the p53DREAM pathway results in loss of checkpoint control. Importantly, many of the p35DREAM pathway genes are involved in many vital cellular processes such as
chromosomal segregation. Hence, the deregulation of their expression contributes to
aneuploidy and chromosomal instability in cancer cells.
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1.1.5 Downregulation expression of cell cycle genes by p53
p53 is a critical tumor suppressor that downregulates many cell cycle genes
leading to cell cycle arrest or apoptosis [15] [59]. It is a transcriptional activator and
repressor, as well [60]. The p53 gene is mutated in more than 50% of human tumors [61].
Many target genes of p53 discovered that mediate its function as a tumor suppressor
(Table 1.1) [69].

Mutations in p53 are oncogenic and contribute to neoplastic transformation [62]
[63]. The activation of p53 is regulated by mouse double minute 2 homolog (MDM2).
MDM2 is an important negative regulator of p53 that inhibits its activity, and it is
overexpressed in sarcoma. Upon activation, the MDM2 gene interacts with p53 by
directly binding to its transactivation domain and inhibits its transcriptional activity
leading to ubiquitination degradation of p53 [64]. It downregulates many cell cycle
genes from G1 through cytokinesis. It responds to stress signals in many ways by
regulation cell cycle pathway, DNA repair, apoptosis, and senescence [65]. It stimulates
many target genes that promote apoptosis, including, but not limited to, PIG3 (tumor
protein p53 inducible protein 3), Bax (BCL2-associated X protein), and PUMA (p53 upregulated modulator of apoptosis) [66].

The p53 gene has an indirect repression mechanism, which is regulated by the
expression of some downstream effectors such as p21, CDN1A, miRNAs, and E2F7 [67].
Upon activation, p53 downregulates many cell cycle genes through the p53-DREAM
16

pathway (figure 2). DREAM and RB-E2F have overlapping functions, and they promote
transcriptional repression and cell cycle arrest by p53. Activation of p53 leads to cell
cycle arrest during G1 and G2/M checkpoints. It recruits the DREAM complex to
downregulate the expression of a set range of essential of the cell cycle progression [7].
In response to DNA damage, p53 activates p21 that inhibits cell division-stimulating
protein (cdk2) activity leading to indirect transcriptional repression and stop cell cycle
progression and ultimately arrests the cell in G0/G1 [7].

Figure 2 indirect repression of the expression of the cell cycle genes through p53p21-DREAM pathway. p53 activates p21 in response to DNA damage, which stops the
cell cycle by inhibiting Cyclin CDK complexes based on [70].
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CYFIP2

BLCAP

BTG1

BLCAP

SYTL1

KRT15

MICALL1

RRAD

FAM84B

SLC9A1

FAM84B

AKAP9

BCL6

ADIRF

PPFIBP1

TXNIP

ADIRF

ITGA3

PPFIBP1

TXNIP

HES1

HES1

DGKA

PSTPIP2

CMBL

WDR63

KRT15

ANXA4

FLRT2

IER5

Table 1.1 Examples of P53 target genes

18

FAM210B SERPINB5

1.1.6 Aberrant expression of cancer/testis (CT) genes in somatic
cells
The processes that drive the evolution of germ cells and tumor cells share similar
biological characteristics. Recognition of the biological features of the trophoblast cells
tumor cells led to propose a hypothesis called the 'trophoblastic theory of cancer', which
suggests that cancer cells emerge from germ cells that unable to continue migrating to the
gonads during embryonic development [34]. Trophoblast cells are known as the cells that
form the outside layer of the blastocyst to become the placenta in mammalian cells [35].
Since then, many genes have been discovered that are expressed in germ cells,
trophoblasts, and tumors, and these are known as cancer/testis (CT) genes [9]. CT genes
encode immunogenic antigens called Cancer Testis Antigens (CTA). These antigens can
evoke cellular and humoral immune responses in patients with cancer [36].
Because of the discovery of CT gene expression in many cancer cell types, one of the
theories proposed that the ‘misexpression’ of germline genes in cancer cells is as a result
of a silenced gametogenic program, it being abnormally activated in somatic cells. Thus,
the activation of gametogenic program is one of the factors that drive tumorigenesis [37].

It is during early embryonic development that the fate of all cells is determined.
The cells become either non-reproductive somatic cells or germ cells that eventually form
the germline that produces an organisms’ gametes, sperm, or eggs [38]. Germline genes
are normally expressed in the male testis or female ovaries and placenta [39]. Somatic
cells silence or turn off germline genes, but cancer cells often misexpress a class of
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germline genes called CT genes. The expression of the germline in malignant cells is
called the soma-to-germline transformation, a de-differentiation phenomenon observed in
somatic cells in model organisms like Drosophila melanogaster and Caenorhabditis
elegans [40]. Misexpression of germline genes appears to be linked to cancer initiation
and progression in mammalian somatic cells. Aberrant expression of CT genes causes
chromosome missegregation and aneuploidy in cancer cells [36]. Loss of CT genes
repression in tumor cells is a hallmark of cancer disease. Thus, understanding genetic and
epigenetic alterations in tumor cells that occur as a result of misexpression of CT is
important, because it can help to understand the mechanisms that contribute to inhibit
expression of the CT genes in somatic cells to protect their fates during development
[40].

CT genes are ectopically expressed in many types of cancer cells, and classified
into two groups, depending on chromosome localization [36]. The first group is CT genes
encoded by X chromosome genes; 10% of these genes are expressed in tumor cells and
contribute to tumor evolution [41]. The second group comprises CT genes that are
encoded by non-X chromosome genes and found on autosomal chromosomes expressed
during meiosis [42]. The molecular and physical functions of most CT genes remain
unclear [36]. Because CT genes are ectopically expressed in many human cancer types, it
is necessary to understand the mechanisms that drive their activation in tumors.
CT genes are frequently expressed in tumor types such as bladder cancer, lung
carcinomas, hepatocellular carcinomas, melanomas, and ovarian cancer [43]. Although
some cancer types show poorly expressed CT genes, such as glioblastoma and clear cell
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renal cell carcinoma (CCRCC), melanomas, and lung carcinomas show abundant
overexpression of CT genes [44]. The melanoma antigen gene (MAGE) family is
frequently overexpressed in lung adenocarcinomas, while semenogelin 1 (SEMG1) is
frequently overexpressed in colon cancer. Basal cell breast cancer shows enriched
expression of melanoma-associated antigen 3 (MAGEA3), actin-like 8 (ACTL8), and
chromosome X open reading frame 6 (CXorf6). Magnoid lung adenocarcinomas show
overexpressed MAGEA1, MAGEA3, MAGEA4, MAGEA12, and CSAG1[44].
Currently, the mechanism underlying how each CT gene is misexpressed in such a wide
variety of cancer cell types remains unknown.

CT proteins evoke an immune response in cancer cells and have an expression
pattern that is specifically associated with tumor cells and not found in most normal
tissues. This makes them unique targets for immunotherapy in cancer treatment [45].
Despite the fact that understanding the expression pattern of these genes would help to
identify driver genes in cancer, few studies have investigated why and how the oncogenic
mechanisms of CT gene expression impact human somatic tissues.

Research on CT genes presents a challenge for scientists. Firstly, most studies that
have analyzed the expression of CT genes have involved just a small number of samples
[46]. Secondly, many CT genes remain uninvestigated in terms of how they abnormally
reactivated and whether their expression can trigger, or is associated with, tumor
progression. Although the mechanisms that drive CT co-expression in somatic and cancer
cells remain poorly understood, ectopic expression of CT genes is known to reflect a ‘cell
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identity crisis. Normal cells are able to change their identity under pathological
conditions. Most cancer cells arise from the epithelial cells that form the skin. In breast
cancer, for instance, cells change their epithelial identity and acquire invasive and
metastatic characteristics – a process which is known as epithelial-mesenchymal
transition (EMT) [47].

In the C. elegans model system, a soma-to-germline transformation occurs as a
result of loss-of-function mutations in a homolog of the tumor-suppressor pRb, called lin35. The loss-of-function of lin-35 leads to misexpression of the germline-specific
gene pgl-1 [48]. Similarly, the mechanism that drives soma-to-germline transformation
in C. elegans might also contribute to the reactivation of CT genes in mammalian somatic
cells, though a variety of factors may influence this transformation in human somatic
cells [49]. Thus, this study hypothesizes that ectopic expression of CT genes in human
somatic tissues is associated with dysfunction of both the transcriptional repressors
DREAM and RB-E2F complexes by oncoproteins.
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1.1.7 Study hypothesis
In our project, we are addressing the factors that drive the soma-to-germline
transformation that occurs in cancer cells in mammalians. In particular, we focus on how
the loss of both transcriptional suppressors can promote ectopic expression of
Cancer/testis genes (CT) in human cancers. Our hypothesis suggests that cancer cell lines
that have Rb and DREAM complex that are functioning normally or that have either
DREAM or Rb is dysfunction can exit cell cycle under limiting condition (figure 3).
However, cancer cells that are lacking both DREAM complex and Rb can not exit cell
cycle therefore they can proliferate normally under limiting growth conditions (figure 1A
and1B). Thus, we propose that misexpression of CT genes in tumor cells is associated
with loss of functions of both DREAM and Rb.

First, we used Flow cytometry to measure the DNA content of 10 cell lines. We
found that the majority of the cell lines, a total of seven of the cell lines arrested in
G0/G1, under limiting growth conditions. A total of three of the cell lines did not arrest in
G0/G1. Next, we analyzed the mRNA expression of many CT genes in proliferating cells
of all the cell lines. However, we did not observe specific gene expression pattern
between all the cell lines. Then, we analyzed the mRNA expression of Rb and DREAM
G0/G1 and G2/M target genes in 8MGBA, NCI-H1299, SW480 cell lines to test if the
misexpression of the CT genes is associated with loss of functions of DREAM or Rb. The
mRNA expression results suggest that DREAM and Rb G0/G1 target genes are still
down-regulated in serum-starved cells as compared to proliferating cells, however low
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fold-change levels might indicate loss of function of either DREAM or Rb. Analysis of
G2/M late cell gene expression in serum starved cells suggest that DREAM is
dysfunctional in SW480 and H1299 cell lines. However, luciferase reporter analyses
revealed that Rb is dysfunctional in SW480 cells. Together, these studies will facilitate
future studies into the link between cell cycle regulation and CT upregulation in cancer
cells.

A

B

Figure 3 Models show how soma-to-germline transformation can occur in human
cancer cells as a result of dysfunction of both DREAM complex and Rb.
(A) A model of DREAM and Rb activity in human cancer cells, both DREAM and
Rb arrest cell cycle in G0/G1, and they can arrest cell cycle even if one of them is
dysfunction, however if they both are dysfunction they cannot arrest cell cycle
expression in response to limiting growth condition.
(B) A model describes how soma-to-germline genes transformation can occur in
human cancer cells.
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1.2 Methods
1.2.1 Cell culture
The human ovarian carcinoma OVCAR3 cells, SKOV3 human ovarian cancer
cells, ES-2 ovarian cells, lung cancer cell line NCI-H1299, human ovarian cancer cells
OVCAR5, and human ovarian cancer cells OVCAR10 were cultured in RPMI medium
supplemented with 10 % fetal bovine serum (FBS). The SW480, MDA-MB-231, T98G,
and 8MGBA cells were cultured in DMEM medium with 1% Glutamax and 10% FBS.
The cells were plated in 6-well plates (250,000 cells) for each well. The cells were
separated into three groups; proliferated cells were cultured for 24 hours to reach 80-90%
confluency. Serum starvation added to the cells for 48 hours. After serum starvation,
serum release added to the cells for 24 hours. Cells were washed once with PBS before
added serum starvation or serum release. At 24,48 h, adherent cells were detached using
trypsin. The cells were starved by 2 mL of serum starvation containing RPMI medium
supplemented with 1% penicillin/streptomycin or DMEM with 1%
penicillin/streptomycin and 1% Glutamax for 48 hours, and re-stimulated by added 2mL
of serum released containing either DMEM or RPMI medium with 20% fetal bovine
serum (FBS), 1% Glutamax and 1% penicillin/streptomycin for 24 hours and seeded at
different times. Proliferating cells were seeded after 24 hours, serum-starved cells after
48 hours, and serum released after 24 hours. All the cell lines were maintained at 37°C
and 5% CO2.
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1.2.2 Flow Cytometry
To measure DNA content, all cell lines were plated in 6 well-plates (125,000 cells
per well). They were grown in DMEM or RPMI medium for 24 hours. The cells were
grown under serum starvation for 48 hours, and serum released for 24 hours after the
serum starvation. The cells were trypsinized and stored in 500 μl of 70% Ethanol at -20
°C overnight. Then, they were centrifuged at 4,000 rpm for 2 minutes at 4 °C. Next, they
were resuspended in PBS that contains 0.25% Triton X-100. They were incubated on ice
for 15 minutes and spun for 2 minutes at 4,000 rpm at 4 °C. They were resuspended in
500μl PBS, 0.5μl of 10μg/mL Rnase A, and 10μl of 1 mg/mL Propidium Iodide (PI).
Finally, they were transferred to the FACS tubes and stored for 30 minutes at room
temperature before analyzed by Flow cytometry.
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1.2.3 RNA extraction
Isolation of total RNA with 500 mL of TRIZOL reagent and incubated overnight.
Chloroform was added and transferred to a phase-lock tube and mixed. Then, it was
incubated at room temperature for 10 minutes. The cells were centrifuged at 4 °C for 15
minutes at 12,000 RCF. Next, the top aqueous layer was transferred to RNase free tube.
Isopropanol was added and mixed and incubated at room temperature for 5 minutes.
Then, the tubes were centrifuged at 4 °C. for 8 minutes at 12,000 RCF. The liquid was
removed, and Ethanol/Nuclease-free water was added and centrifuged for 5 minutes at
12,000 RCF. The liquid was removed from the tubes and centrifuged for 1 minute at
12,000 RCF. The liquid was removed, and the tubes left open to dry by air for less than 4
minutes. Lastly, Nuclease-free water was added and stored at -70 °C overnight.
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1.2.4 Reverse Transcription
The concentration of RNA was between 200-500ng, and RNase-free water total 8 µL. We
made the first DNase l treatment master mix a total of 2µL per sample. The first master
mix for RNA 500ng concentration was 1 µL of 10x DNase buffer, 0.25 µL of DNase I,
and 0.75µL of RNase-free water per sample. The mix was added to each sample (2µL per
sample). The tubes were incubated for 15 minutes at room temperature. Next, mM EDTA
was added to the tubes (1µL per sample). The tubes incubated for 10 minutes at 65°C.
The tubes were then transferred to an ice bath. We prepared RT-PCR master mix that
contains of 10x RT buffer (0.2 µL), 25xdNTP Mix (100 mM) (0.8 µL), 10x RT Random
Primers (0.2 µL), MultiScribe RTase (1 µL), and Nuclease-free water (3.2 µL) the total
volume reaction was 9 µL per sample. A total of 9 µL of the mix was added to each
sample and mixed and centrifuged. The samples ran on ABI simpliAmp cycler. The
samples were diluted 1:2.5 or 1:5 per 500ng RNA amount and the ddH2O was 30 µL or 8
µL after the dilution they were transferred to a fresh 1.5 mL tube.
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1.2.5 Quantitative PCR
We made a dilution with ddH2O for each Cancer/Testis gene (CT) that we used before
making the primers. Next, we made a master mix reaction that contains 5 µL of 2x SYBR
Green (ABI), 0.5 µL of 10µM Forward primer, 05 µL of 10µM Reverse primer, 2.0 µL
of ddH2O per sample. The total volume was 8 µL per well. The plate was centrifuged at
1500 rpm for 2 minutes and added to the qPCR machine and ran on ABI QuantStudio 3.
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1.2.6 Transfection and luciferase assays
To test promoter activities of DREAM with luciferase reporter assays, H1299, SW480
cell lines were cultured in RPMI medium supplemented with 10 % fetal bovine serum
(FBS) or DMEM medium with 1% Glutamax and 10% FBS. SW480-NCI-H1299 cells
were plated in 24 well-plates (25000 cells per well) and incubate for 24 hours. Each well
was washed with 0.5 mL PBS. The medium was replaced with serum-free media
containing RPMI medium supplemented with 1% penicillin/streptomycin or DMEM with
1% penicillin/streptomycin and 1% Glutamax for 24 hours followed by transfected.
For transfection, Lipofectamine 3000 reagent mixes were made that contain: first mix 25
µL of serum-free media, 50ng pGL4.70 Renilla, and 200ng pGL4.10 reporter, and 0.5 of
µL P3000 reagent per well. The second mix was 25 µL of serum-free media, and 1 µL of
Lipofectamine 3000 regent. The second mix was added to all the tubes of the first mix.
The tubes were incubated at room temperature for 15 minutes. Next, 50 µL of the mix
was added to each well and incubated for 48 hours. The reporters are Bub1 (WT), Bub1
(CHR), ORC1(WT), and ORC1(E2F). After 48 hours, the wells were washed with 0.5
mL PBS, and then 100 µL 1x Passive lysis buffer (PLB) was added to each well. The
wells were incubated and shacked for 15 minutes. Next, 20 µL of lysate was transferred
into a white 96-well plate, first: 20 µL of Luciferase Assay regent II (Luc) was added to
each well, the reading for the plate was done by using Tecan Spark-Luciferase program,
second 20 µL of Stop and Glo (S&G) was added to each well and the reading for the
plate was done by using Tecan Spark (Renilla program).
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1.3 Results

1.3.1 Majority of human cancer cell lines tested arrest their cell
cycle in growth-limiting conditions
We are interested in understanding the key factors that drive CT genes activation
in malignant cells. We hypothesize that loss-of-function of both cell cycle transcriptional
repressor factors DREAM and Rb causes insensitivity to growth-limiting conditions.
Therefore, we first aimed to identify human cancer cell lines that arrest versus cell lines
that fail to arrest in limiting growth conditions, which would indicate that cell lines that
loss of both DREAM and Rb functions cannot arrest in G0/G1.

To categorize the response of human cancer cell lines to growth-limiting
conditions, we measured the DNA content of the proliferated and serum-starved and
serum released cells among ten cell lines. Using Propidium Iodide staining and flow
cytometry, the DNA content of serum-starved cells was compared to normally
proliferating and serum released cells. Serum starved cells were incubated in serum-free
media for 48 hours, and serum released cells were serum-starved for 48 hours and then
re-stimulated with media containing serum for 24 hours. We tested ten of human cancer
cell lines, including breast cancer cell line (MDA-MB-231), human ovarian cancer cell
line (ES-2), human ovarian carcinoma cell line (OVCAR-3) , ovarian cancer cell line
(OVCAR-5), glioblastoma cell line (T98G), glioblastoma cell line (8MGBA), colon
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adenocarcinoma cell line (SW480), lung cancer cell line (NCI-H1299), ovarian cancer
cell line (SKOV3), and ovarian cancer cell line (OVCAR-10).
To assess whether cells were sensitive to serum starvation, we measured the
percentages of total cells in G1/S (2n) and G2/M (4n) in serum-starved cells compared to
normal proliferating cells (figure 4A and 4B), (figure 5A and 5B), (figure 6A and 6B),
and (figure 7A and 7B). We found that 7 out of 10 cell lines were sensitive to growthlimiting conditions, indicating that they arrested in G0/G1. NC1-H1299 cells in G1/S
increased from 55.65% to 89.70% in response to growth-limiting conditions, with a
corresponding G2/M decrease from 29.30% to 4% (figure 4B). OVCAR-5 cells in G1/S
increased from 65.57% to 83.87% in response to growth-limiting conditions, with a
corresponding G2/M decrease from 20.51% to 8.13% (figure 4B). SW480 cells in G1/S
increased from 65.57% to 74% in response to growth-limiting conditions, with a
corresponding G2/M decrease from 18.49%% to 8.01% (figure 4B). MDA-MB-231 cells
in G1/S increased from 63.30% to 81.80% in response to growth-limiting conditions,
with a corresponding G2/M decrease from 25.40% to 13.30% (figure 5B). SKOV-3 cells
in G1/S increased from 52.67% to 76.73% in response to growth-limiting conditions,
with a corresponding G2/M decrease from 28% to 14.57% (figure 5B). 8MGBA cells in
G1/S increased from 64.50% to 84.30% in response to growth-limiting conditions, with a
corresponding G2/M decrease from 22.53% to 9.97% (figure 5B). T98G cells in G1/S
increased from 44.33% to 71.30% in response to growth-limiting conditions, with a
corresponding G2/M decrease from 15.97% to 8.93% (figure 6B). These results indicate
that NC1-H1299, OVCAR-5, SW480, MDA-MB-231, SKOV-3, 8MGBA, and T98G cell
line arrested in G0/G1 in limiting growth conditions.
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In contrast, of the ten cell types, three cell lines were insensitive to growth
conditions. ES-2 cells in G1/S and G2/M were 52-57% and 33-35% in all conditions
(Figure 7B). OVCAR-3 cells in G1/S were 60-67%, and G2/M were 18-25% in all
conditions (Figure 7B). OVCAR-10 cells in G1/S were 51-52%, and in G2/M, they were
26% in all conditions (Figure 7B). These results indicate that ES-2, OVCAR-3, and
OVCAR-10 did not arrest in G0/G1 in limiting growth conditions.

In addition, we tested whether the repression of cell cycle genes during
quiescence can be rescued by re-stimulation after serum starvation in OVCAR-5 cells
that arrested in G0/G1. As expected, the results displayed an increase in total cells in
G1/S and G2/M upon re-stimulation (figure 4A). Upon re-stimulation, the cells re-entered
the cell cycle and proliferated normally in G1/S and G2/M and show peaks in G1 and
G2/M. The cell percentage in G0/G1 is 65.57% and 20.51% in G2/M in proliferated cells.
While it is 83.87% in G0/G1 and 8.13 in G2/M. However, it is 60.62% in G0/G1 and
26.37% in G2/M in released cells (figure 4B).

In total, 7 of cell lines arrested in response to serum starvation, including NC1H1299, OVCAR-5, SW480, MDA-MB-231, SKOV-3, 8MGBA, and T98G (figure 4A
and 4B), (figure 5A and 5B) and (figure 6A and 6B). Three of the cell lines did not
respond to serum starvation, including ES-2, OVCAR-3, and OVCAR-10 (figure 7A and
7B).
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Taking together, flow cytometry results revealed that the percentages of cells in
G0/G1 and G2/M phases of the cell cycle significantly change in both proliferating and
serum-starved cells in NC1-H1299, OVCAR-5, SW480, MDA-MB-231, SKOV-3,
8MGBA, and T98G cell lines because of the cell arrested in G0/G1, and decreased in
G2/M after serum starvation compared with proliferating cells. These cell lines that might
have Rb or DREAM function correctly, are likely to be arrested in G0/G1 under growthlimiting conditions.

However, ES-2, OVCAR-3, and OVCAR-10 cell lines proliferated normally in
G1, S, and G2/M even after serum starvation, and it might be as a result of loss activities
of both DREAM complex and Rb that hinder cell cycle arrest following limiting growth
conditions. These cell lines might lack both Rb and DREAM complex. Because of that,
they are unable to exit the cell cycle. So, they proliferate normally.
Thus, we are more interested in the cell lines that are arrested in G0/G1 (NC1-H1299,
OVCAR-5, SW480, MDA-MB-231, SKOV-3, 8MGBA, and T98G to test how DREAM
or Rb arrest cell cycle genes in G0/G1 in response to limiting growth conditions and
whether one of them is dysfunctional in these cell lines.
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A

B

Figure 4 DNA content of the proliferating, serum-starved, and serum released cells
of NCI-H1299, SW480, and OVCAR5 cell lines as measured by flow cytometry.
(A) In response to serum starvation, H1299, SW480, and OVCAR5 cell lines showed
only one peak in G0/G1 phase indicating that they arrested in G0/G1.
(B) The total percentage of the cells of H1299, SW480, and OVCAR-5 cell lines are
increased in G0/G1 phase and significantly decreased in G2/M phase in H1299,
and OVCAR-5 after serum starvation for 48 hours.
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A

B

Figure 5 DNA content of the proliferating, serum-starved, and serum released cells
of MDA-MB-231, SKOV3, and 8MGBA cell lines as measured by flow cytometry.
(A) In response to serum starvation, MDA-MB231, SKOV3, and 8MGBA cell lines
show only one peak in G0/G1 phase indicating that they arrested in G0/G1.
(B) The total percentage of the cells of MDA-MB231, SKOV3, and 8MGBA cell
lines are increased in G0/G1 phase and significantly decreased in G2/M phase
after serum starvation for 48 hours.
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A

B

Figure 6 DNA content of the of the proliferating, serum-starved, and serum released
cells T98G cell line as measured by flow cytometry.
(A) In response to serum starvation, T98G cell line showed only one peak in G0/G1
phase indicating that it arrested in G0/G1.
(B) The total percentage of the cells of T98G cell line are increased in G0/G1 and
significantly decreased in G2/M phase after serum starvation for 48 hours.
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A

B

Figure 7 DNA content of the of the proliferating, serum-starved, and serum released
cells of ES-2, OVCAR-3, and OVCAR-10 cell lines as measured by flow cytometry.
(A) ES-2, OVCAR-3, OVCAR-10 cell lines were insensitive to limiting growth
conditions, and they show two peaks after serum starvation for 48 hours in G1/S
and G2/M after serum starvation for 48 hours.
(B) The total percentage of the starved cells of ES-2, OVCAR-3, and OVCAR-10 did
not significantly change in compared with proliferating and serum starved cells
indicating that ES-2, OVCAR-3, and OVCAR-10 did not arrest in G0/G1 in
limiting growth conditions.
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1.3.2 Exploring a potential relationship between CT genes
expression and loss of DREAM and Rb function
If CT gene misexpression is linked to loss of DREAM and Rb function, then we
expect that CT gene expression would be increased in cancer cells that are insensitive to
serum starvation as compared to cells that arrest in growth-limiting conditions. We tested
the mRNA expression of 12 known CT genes among ten cancer cell lines using reverse
transcriptase quantitative PCR (RT-qPCR). Representative CT genes tested include
MAGEA4, TTK, SSX2, LIN28B, PIWIL, CTAGE2, SKA3, MAGEA12, MAGEA3,
MAGEA6, YBX2, and KCTD19 (Table 1.2).

CT genes are expressed in some human cancer cell lines that cannot arrest cells
cycle in response to limiting growth conditions and proliferated normally in G1/S and
G2/M. For example, MDA-MB3 cells expressed TTK and CTAGE2 genes (figure 8).
OVCAR3 proliferated cells expressed TTK, SSX2, LIN28B, PIWIL, SKA3, YBX2, and
CTAG2 genes (Figure 8) and (Figure 9). OVCAR10 cells expressed TTK, SSX2, and
LIN28B (Figure 8). ES-2 expressed TTK and CTAG2 genes (Figure 8).

In addition, CT genes are expressed in some human cancer cell lines that can
arrest in G0/G1 under limiting growth conditions. For instance, NCI-H1299 cells
expressed MAGE4, TTK, and LIN28B genes (figure 8). SW480 cells expressed TTK,
PIWIL, SKA3, YBX2, and KCTD19 genes (figure 8) and (figure 9). OVCAR5 and
SKOV3 cells expressed TTK and CTAG2 genes (figure 8). 8MGBA cells expressed
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many CT genes such as TTK, SSX2, CTAG2, SKA3, MAGEA12, MAGEA3, MAGEA6,
and KCTD19 (figure 8) and (figure 9). Finally, T98G expressed TTK and SKA3 genes
(figure 8) and (figure 9).

Taking together, we did not find differences between two mRNA expression
between the two groups. There are some cell lines that share similar CT genes expression
patterns. For instance, TTK genes are expressed in all the cell lines that we tested. We
discriminated between these two groups and select only cells that arrested in G0/G1 in
limiting growth conditions. Because we did not observe differences of CT gene
expression between cells that can arrest and cells that cannot. We next asked if
misexpression of CT genes might be associated with dysfunction in either or both Rb or
DREAM.
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Figure 8 mRNA expression of CT genes in proliferation cells of H1299, SW480,
OVCAR-5, SKOV3, 8MGBA, T98G, MDA-MB-231, OVCAR-3, OVCAR-10,
and ES-2 cell lines was analyzed by qPCR.
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Figure 9 mRNA expression of CT genes in proliferation cells of SW480, 8MGBA,
T98G, and OVCAR-3 cell lines was analyzed by qPCR.
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PRR23A

PRR23B

PRSS37

PRSS41

PSG11

PSG3

PSKH2

PSMA8

PTF1A

R3HDML

RAD51AP2

RBMXL2

RBPJL

RGSL1

RIMBP3

RIMBP3C

RNASE8

RNF113B

RNF133

RNF148

ROPN1

ROPN1B

S100A7L2

SAGE1

SCN10A

SEL1L2

SHCBP1L

SKA3

SLC25A2

SLC25A52

SLCO6A1

SLFNL1

SMC1B

SMCP

SOX30

SPA17

SPACA3

SPATA12

SPATA16

SPATA17

SPATA31D4

SPATA33

SPATA8

SPINT3

SPRR4

SSMEM1

SSX1

SSX2

SUN3

SUN5

SYCE1L

SYCN

SYCP3

SYNGR4

TAS2R1

TCEB3C

TCP11

TDRD12

TEKT5

TEX101

TEX13B

TEX19

TEX33

TEX35

TEX38

TEX43

TMCO2

TP53TG3B

TPPP2

TPTE

TRIM48

TSPAN16

TXNDC2

USP29

WBSCR28

WDR87

WFDC10A

WFDC6

YBX2

ZAR1L

ZC2HC1B

ZDHHC19

ZNF645

ZSWIM2

Table 1.2 Examples of cancer/testis genes (CT)
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1.3.3 Early cell cycle genes are primarily repressed by both
DREAM and Rb
To test whether the DREAM complex or Rb are inactive in the cancer cell lines,
we selected for further analyses SW480, NCI-H1299, and 8MGBA cells. We tested the
mRNA expression of DREAM and Rb target genes in quiescent cells (serum-starved) and
proliferated cells (serum-released) in SW480, NCI-H1299, and 8MGBA cell lines (Table
1.3). Our hypothesis suggests that cell lines that cannot arrest are dysfunctional in both
Rb and DREAM. However, cell lines that can arrest may be dysfunctional in either Rb or
DREAM. Thus, we expect that either DREAM Complex or Rb work to repress CT genes
in G0/G1 in the serum-starved cells in SW480, NCI-H1299, and 8MGBA starved cells.
Therefore, one of them is broken.

We tested early cell cycle genes (G1/S), and late cell cycle genes (G2/M) using
RT-qPCR analysis on serum-starved and serum released human cancer cell lines. We
selected SW480, H1299, and 8MGBA cell lines.

To test the DREAM or Rb regulation of early cycle genes, we assessed expression
levels of MCM5, ORC1, and CDC45 in quiescent cells (serum-starved) compared to
proliferating cells (serum released). MCM5 has significantly downregulated in SW480
serum-starved cells compared with proliferating cells with 12-fold change, suggesting
that MCM5 gene is repressed by DREAM and Rb complexes in G0/G1 (figure 10).
MCM5 is also downregulated in H1299 serum-starved cells with 3.8-fold repression and
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8MGBA with 2.7-fold repression (figure 10). However, the repression in H1299 and
8MGBA cell lines is not significant. Similarly, ORC1 is also significant downregulated in
SW480 serum-starved cells compared with proliferating cells with the 7.5-fold change,
and it is downregulated in H1299 starved- cells with 2.2 fold change compared to
proliferated cells. It is also downregulated in 8MGBA with 2.4 fold change (figure 10).
The expression of the CDC45 gene is lowly expressed in SW480 starved-cells with 3.6
compared to proliferating cells (figure 10). In addition, it is lowly expressed in H1299
serum-starved cells with a 6.7-fold change and downregulated in serum-starved 8MGBA
with a 3.4-fold change (figure 10).

Taken together, these results testing early cell cycle genes in NCI-H1299 and
SW480 and 8MGBA cell lines suggests that either DREAM or Rb are functional.
However, the lower fold change observed in NCI-H1299 and 8MGBA serum-starved
cells as compared to proliferating cells suggest that 1 of the factors may be dysfunctional.
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Figure 10 mRNA expression of early cell cycle genes (MCM5, ORC1, and CDC45)
in the proliferated cells (yellow) and the quiescent cells (gray) in 8MGBA, H1299,
SW480 cell lines was measured by qPCR and normalized to U6 expression. The
mRNA expression results suggest that DREAM and Rb G0/G1 target genes are still
down-regulated in serum-starved cells as compared to proliferating cells.
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1.3.4 Late cell cycle genes are primarily repressed by DREAM
Since the only DREAM represses late cell cycle genes, we assess expression
levels of CCNB2, PBK, and BUB1 in quiescent cells (serum-starved) and proliferating
cells (serum released). The expression of CCNB2 gene is downregulated in SW480 cells
with 1.7 fold changes and NCI-H1299 with 1.3 fold changes and 8MGBA starved cells
with 4 fold changes (figure 11). The expression of the PBK gene is partially repressed in
SW480 cells with 2 fold change, and it is lowly expressed in H1299 quiescent cells with
3.9 fold change, and in 8MGBA starved cells with 5.8 fold change (figure 11). The
expression of the BUB1 gene is substantially impaired in SW480 serum-starved cells
with 1 fold change (figure 11). It is partially downregulated in H1299 quiescent cells with
fold change 4.9 (Figure 11), and it is downregulated in 8MGBA with fold change 5.9
(figure 11)
Taken together, these results testing late cell cycle genes in NCI-H1299 and
SW480 and 8MGBA cell lines suggest that DREAM may be dysfunctional in NCI-1299
and SW490, but the results are ambiguous.
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Figure 11 mRNA expression of late cell cycle genes (CCNB2, PBK, and
BUB1) in the proliferated cells (blue) and the quiescent cells (gray) in
8MGBA, H1299, SW480 cell lines was measured by qPCR and normalized
to U6 expression. Analysis of G2/M late cell cycle genes expression in serum
starved cells suggest that DREAM is dysfunctional in SW480 and H1299 cell
lines.
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Litovchick
2007

Chicas 2010

DREAM

RB

ANLN (Anilin)

+

+

AURKA (AIK-1)

+

+

AURKB (AIM-1)

+

-

BIRC5 (Survivin)

+

-

BRCA1

+

+

BUB1

+

-

BUB1B (BUBR1)

+

-

CCNA1

+

-

CCNA2

+

-

CCNB1

+

-

CCNB2

+

-

CDC20

+

-

CDC25A

+

+

CDC25B

+

-

CDC25C

+

-

CDC45

+

+

CDC6

+

+

CDK1 (CDC2)

+

+

CENPA

+

-

CENPE

+

+

Gene name
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CENPF

+

+

CHAF1B

+

-

CHEK1 (CHK1)

+

+

CIT

+

+

CKS1B (CKS1)

+

+

CKS2

+

+

DCK

+

+

DDX11 (CHLR1)

+

+

DHFR

+

+

DLGAP5

+

+

E2F1

+

+

E2F5

+

-

E2F8

+

+

ECT2

+

-

EZH2

+

-

EXO1

+

+

FANCG

+

+

FEN1

+

+

FOXM1 (MPP2)

+

+

GJB2

+

-

HMGB1

+

+

HMGB2

+

+

ING1

+

+
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KI67 (MKI67)

+

+

KIF2C (MCAK)

+

+

KIF4A

+

+

KIF11 (KNSL1)

+

+

KIF23 (KNSL5)

+

+

KIFC1 (HSET)

+

+

LIG1

+

-

MAD2L1 (MAD2)

+

+

MCM2

+

-

MCM3

+

+

MCM4

+

+

MCM5

+

+

MCM6

+

-

MCM7

+

+

MYC (c-myc)

+

-

NCAPH (XCAP-H)

+

+

NEK2

+

+

ODC1

+

-

ORC1

+

+

PCNA

+

+

PLK1

+

+

PLK4 (Sak-b)

+

+

POLA1

+

+
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POLD1

+

+

PRC1

+

+

PRIM2 (p58)

+

+

RAD21

+

-

RAD51

+

+

RAD54L

+

+

RPA1

-

-

RPA3

-

-

RRM1

+

+

RRM2

-

-

SLC7A5

-

-

STMN1

-

+

TACC3

-

-

TERT

-

-

TK1

-

+

TMPO (LAP-2)

+

+

TOP2A

+

-

TOPBP1

+

-

TYMS

+

+

SMC2 (SMC2L1)

+

-

SMC4 (SMC2L1)

-

-

SUV39H1

+

-

Table 1.3 Examples of DREAM and Rb target genes
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1.3.5 DREAM is functional normally in SW480, and H1299 cell
lines
To test whether DREAM or Rb are functioning in the SW480 and H1299 cell
lines, we performed a luciferase reporter assay. We tested DREAM and RB functions in
quiescent cells (starved cells) and whether either one of them works or not. In SW480
serum-starved cells, we did not observe an increase in activity of the ORC1 promoter
when the E2F binding site is mutated (ORC1 E2F) as compared to the wild-type ORC1
promoter (ORC1 WT). This might reflect to loss of function of the Rb (Figure 12). In
contrast, the wild-type ORC1 promoter is repressed compared to ORC1 E2F, suggesting
that Rb is functional. A small increase the activity of Bub1 promoter when the CHR
binding site is mutated (Bub1 CHR) as compared to Bub1 WT suggests that DREAM is
functional in SW480 and NCI H1299 (Figure 12).

Taken together, the results of the luciferase assay suggest that Rb is disfunctional
in SW480, but results for DREAM are ambigous compared to the late cell cycle gene
expression analysis (Figure 12).
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Figure 12 The activity of E2F binding sites (Orc1) and CHR binding sites (Bub1) in
the wild type (WT) (orange) and the serum-starved cells (grey) in the SW480 and
H1299 cell lines were analyzed by luciferase reporter assay.
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1.4 Discussion
Previous studies reported that the Cancer/testis genes (CT) are ectopically
expressed in various types of human cancers. They are expressed in bladder, lung,
ovarian, melanoma, and breast tumors [36]. These genes are exclusively expressed in
male germ cells and placenta [39]. The factors that drive the misexpression of CT genes
that impacts somatic cells expression and promote the development of cancer remain
poorly understood. Our study hypothesized that misexpression of CT genes in cancer
cells is associated with dysfunction of both the transcription suppressors DREAM
complex and Rb that regulate cell cycle genes through the p53-DREAM pathway.

The flow cytometry results revealed that serum-starvation induced cancer cells to
arrest in G0/G1 in respond to limiting growth conditions. Thus, the total percent of the
cells decreased in S, G2, and M phase indicating that these cell lines arrested in the
G0/G1 phase and Rb or DREAM function as normal (figure 4A, and 4B), (figure 5A and
5B), and (figure 6A and 6B). However, the cell lines that were insensitive to serum
starvation might have a loss of functions of both DREAM and RB (figure 7A, and 7B).

Furthermore, one of the unexpected results that gene expression analysis of all CT
genes revealed that they have similar gene expression patterns indicating that we did not
find a difference in gene expression between cells that can arrest and the cells that cannot
in limiting growth conditions (figure 8) and (figure 9). Thus, maybe we should test more
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CT genes to find an appropriate CT with specific expression pattern that is expressed
only in cancer cells that are lacking both DREAM and Rb and cannot exit cell cycle.
Moreover, gene expression analysis of early cell cycle genes G0/G1 (MCM5, ORC1, and
CDC45), and late cell cycle genes G2/M (PBK, BUB1, CCNB2) (figure 10) and (figure
11) revealed that that either the DREAM or RB is dysfunction in G0/G1. The gene
expression analysis of late cell cycle genes (CCNB2, PBK, and BUB1) revealed
unexpected results that suggest that DREAM is dysfunctional in SW480 and H1299 cell
lines.

Furthermore, to test more directly whether DREAM or Rb is dysfunctional in
SW480 and H1299, we performed a Luciferase Reporter assay. In contrast to the mRNA
gene expression results, the results revealed that Rb may be dysfunctional in SW480 cells
(figure 12). Together, these results do not confirm that loss of DREAM or Rb is linked to
activation of CT gene expression in human cancer cell lines.
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1.5 Conclusion
Our study indicates the critical role of DREAM complex in regulating cell cycle
genes in early cell cycle phases G0, G1 by binding to E2F or E2F and CLE sites, and late
cell cycle genes G2/M by binding to CHR or CHR and CDE sites. It remains unclear how
the molecular functions of the DREAM complex differ from Rb. How do they work
together or overlap to repress cell cycle genes? It is unclear how p53 influences the P53DREAM pathway to repress cell cycle in G0/G1 and G2/M or if other unknown genes
have similar functions to repress or active cell cycle genes. However, in order to test p53
function, additional studies such as western plot in p53 knockout cells have to be
conducted. Despite these results, much remains to be learned about how DREAM
complex and the pocket proteins regulate cell cycle genes through the P53-DREAM
pathway. In particular, concerning their roles in the soma-to-germline transformation that
could be associated with cancer development in human mammalian cells.

Although unexpected results, our study may provide an insight into the functions
of DREAM complex and Rb as transcriptional repressors through the cell cycle genes,
and how dysfunction of both of them might contribute to promoting tumors development.
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